Pular para o conteúdo principal
Ranking Invest

KROS - Keros Therapeutics, Inc.

Segmento: HealthcareKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 234.56 Mi
IVR
-0.12Índice proprietário de comparação relativa: -0,12.
IVR2
-1.34Leitura proprietária complementar: -134%.
MLL
-1.34Leitura proprietária complementar: -134%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 262.32 Mi

Dívida Líquida

-$ 257.61 Mi

L4T

-$ 83.16 Mi

MM4T

-20078.25%

Indicadores Básicos

ROE

-31.70%

Índices de Previsibilidade

Receita Líquida

G1.20

Lucro

C0.27

Margem

E1.32

Índices de Tendência

Receita Líquida

C4.29

Lucro

C2.40

Margem

D-0.95

Índices de Endividamento

DIV/PAT

-0.98

DIV/L4T

3.10

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.